ImmuCell Corporation (ICCC)vsNovartis AG ADR (NVS)
ICCC
ImmuCell Corporation
$11.00
-0.18%
HEALTHCARE · Cap: $99.79M
NVS
Novartis AG ADR
$154.21
+1.37%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 189291% more annual revenue ($56.69B vs $29.93M). NVS leads profitability with a 22.5% profit margin vs -1.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ICCC
Hold42
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.1%
Fair Value
$17.60
Current Price
$11.00
$6.60 discount
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$154.21
$61.48 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 28.4% year-over-year
Earnings expanding 31.3% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -1.9% — below average capital efficiency
Currently unprofitable
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on Revenue Growth, EPS Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ICCC profiles as a growth stock while NVS is a value play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.57 — expect wider price swings.
ICCC is growing revenue faster at 28.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 42/100), backed by strong 22.5% margins. ICCC offers better value entry with a 63.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?